475830 — Orum Therapeutics Income Statement
0.000.00%
Last trade - 00:00- KR₩374bn
- KR₩284bn
- KR₩21bn
Annual income statement for Orum Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 75.9 | 135,418 | 20,906 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 25,536 | 43,724 | 39,811 | 29,241 |
| Operating Profit | -25,536 | -43,648 | 95,607 | -8,335 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -25,164 | -63,093 | 67,898 | -5,315 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -25,164 | -63,319 | 68,217 | -5,740 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -25,164 | -63,319 | 68,217 | -5,740 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -25,164 | -63,319 | 68,217 | -5,740 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -1,202 | -3,026 | 3,253 | -424 |
| Dividends per Share |